Linical Co., Ltd. (2183.T)
JPY 330.0
(0.92%)
JPY 330.0
(0.92%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 338.26 Million JPY | -66.32% |
| 2022 | 1 Billion JPY | 27.06% |
| 2021 | 790.48 Million JPY | 46.4% |
| 2020 | 539.96 Million JPY | 11.8% |
| 2019 | 482.99 Million JPY | -15.03% |
| 2018 | 568.45 Million JPY | -56.14% |
| 2017 | 1.29 Billion JPY | -10.47% |
| 2016 | 1.44 Billion JPY | 8.76% |
| 2015 | 1.33 Billion JPY | 204.47% |
| 2014 | 437.13 Million JPY | -2.68% |
| 2013 | 449.18 Million JPY | -27.17% |
| 2012 | 616.78 Million JPY | 45.4% |
| 2011 | 424.19 Million JPY | 186.84% |
| 2010 | 147.88 Million JPY | -45.95% |
| 2009 | 273.61 Million JPY | -8.94% |
| 2008 | 300.47 Million JPY | 1.31% |
| 2007 | 296.58 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -82 Million JPY | -196.79% |
| 2023 Q1 | 3.53 Million JPY | -99.17% |
| 2023 Q3 | 74.64 Million JPY | -57.44% |
| 2023 FY | 338.26 Million JPY | -66.32% |
| 2023 Q4 | 84.72 Million JPY | 13.5% |
| 2023 Q2 | 175.37 Million JPY | 4865.26% |
| 2022 FY | 1 Billion JPY | 27.06% |
| 2022 Q4 | 426.84 Million JPY | 292.66% |
| 2022 Q3 | 108.7 Million JPY | -72.26% |
| 2022 Q2 | 391.85 Million JPY | 409.16% |
| 2022 Q1 | 76.96 Million JPY | -71.02% |
| 2021 Q1 | 67.65 Million JPY | -82.33% |
| 2021 Q2 | 184.95 Million JPY | 173.4% |
| 2021 Q3 | 272.28 Million JPY | 47.22% |
| 2021 Q4 | 265.59 Million JPY | -2.46% |
| 2021 FY | 790.48 Million JPY | 46.4% |
| 2020 Q2 | 185.63 Million JPY | 193.09% |
| 2020 Q3 | 170.9 Million JPY | -7.93% |
| 2020 FY | 539.96 Million JPY | 11.8% |
| 2020 Q4 | 382.84 Million JPY | 124.01% |
| 2020 Q1 | -199.41 Million JPY | -336.92% |
| 2019 Q2 | 214.86 Million JPY | 1280.87% |
| 2019 Q1 | 15.56 Million JPY | -85.83% |
| 2019 Q3 | 168.39 Million JPY | -21.63% |
| 2019 Q4 | 84.17 Million JPY | -50.02% |
| 2019 FY | 482.99 Million JPY | -15.03% |
| 2018 FY | 568.45 Million JPY | -56.14% |
| 2018 Q4 | 109.79 Million JPY | 58.32% |
| 2018 Q3 | 69.35 Million JPY | -80.0% |
| 2018 Q2 | 346.71 Million JPY | 714.01% |
| 2018 Q1 | 42.59 Million JPY | -89.23% |
| 2017 Q4 | 395.42 Million JPY | 8.84% |
| 2017 FY | 1.29 Billion JPY | -10.47% |
| 2017 Q2 | 377.07 Million JPY | 135.41% |
| 2017 Q3 | 363.32 Million JPY | -3.65% |
| 2017 Q1 | 160.17 Million JPY | -58.0% |
| 2016 FY | 1.44 Billion JPY | 8.76% |
| 2016 Q3 | 318.39 Million JPY | -38.87% |
| 2016 Q2 | 520.87 Million JPY | 129.58% |
| 2016 Q4 | 381.36 Million JPY | 19.78% |
| 2016 Q1 | 226.88 Million JPY | -26.61% |
| 2015 FY | 1.33 Billion JPY | 204.47% |
| 2015 Q4 | 309.14 Million JPY | 12.47% |
| 2015 Q3 | 274.86 Million JPY | -50.76% |
| 2015 Q2 | 558.2 Million JPY | 195.73% |
| 2015 Q1 | 188.75 Million JPY | 41.9% |
| 2014 FY | 437.13 Million JPY | -2.68% |
| 2014 Q4 | 133.02 Million JPY | -1.77% |
| 2014 Q3 | 135.41 Million JPY | 10.79% |
| 2014 Q2 | 122.22 Million JPY | 162.99% |
| 2014 Q1 | 46.47 Million JPY | -70.99% |
| 2013 Q1 | 50.27 Million JPY | -72.93% |
| 2013 FY | 449.18 Million JPY | -27.17% |
| 2013 Q3 | 100.63 Million JPY | -27.12% |
| 2013 Q4 | 160.2 Million JPY | 59.19% |
| 2013 Q2 | 138.07 Million JPY | 174.65% |
| 2012 Q3 | 107.68 Million JPY | -37.5% |
| 2012 Q1 | 151.09 Million JPY | -6.85% |
| 2012 Q2 | 172.29 Million JPY | 14.03% |
| 2012 Q4 | 185.71 Million JPY | 72.46% |
| 2012 FY | 616.78 Million JPY | 45.4% |
| 2011 FY | 424.19 Million JPY | 186.84% |
| 2011 Q1 | 9.75 Million JPY | -53.51% |
| 2011 Q2 | 141.59 Million JPY | 1352.15% |
| 2011 Q3 | 110.62 Million JPY | -21.87% |
| 2011 Q4 | 162.21 Million JPY | 46.63% |
| 2010 FY | 147.88 Million JPY | -45.95% |
| 2010 Q2 | 83.64 Million JPY | 91.37% |
| 2010 Q1 | 43.7 Million JPY | -48.2% |
| 2010 Q3 | -434 Thousand JPY | -100.52% |
| 2010 Q4 | 20.97 Million JPY | 4932.49% |
| 2009 Q1 | 123.6 Million JPY | -23.02% |
| 2009 FY | 273.61 Million JPY | -8.94% |
| 2009 Q4 | 84.37 Million JPY | 465.16% |
| 2009 Q3 | -23.1 Million JPY | -126.04% |
| 2009 Q2 | 88.74 Million JPY | -28.2% |
| 2008 Q4 | 160.56 Million JPY | 356.2% |
| 2008 Q2 | 60.99 Million JPY | 0.0% |
| 2008 FY | 300.47 Million JPY | 1.31% |
| 2008 Q3 | 35.19 Million JPY | -42.3% |
| 2007 FY | 296.58 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | 11.91% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | 164.198% |
| GNI Group Ltd. | 8.09 Billion JPY | 95.821% |
| Trans Genic Inc. | 4.08 Million JPY | -8180.685% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | 123.524% |
| Soiken Holdings Inc. | -662.2 Million JPY | 151.082% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | -144.845% |
| AnGes, Inc. | -7.43 Billion JPY | 104.548% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 126.26% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 104.703% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | -81.187% |
| NanoCarrier Co., Ltd. | -780 Million JPY | 143.367% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | 129.341% |
| CanBas Co., Ltd. | -1.2 Billion JPY | 127.979% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | 141.637% |
| RaQualia Pharma Inc. | -323.66 Million JPY | 204.512% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | 127.726% |
| Kidswell Bio Corporation | -1.42 Billion JPY | 123.787% |
| PeptiDream Inc. | 3.03 Billion JPY | 88.858% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | 117.45% |
| Ribomic Inc. | -1.02 Billion JPY | 133.026% |
| SanBio Company Limited | -2.64 Billion JPY | 112.794% |
| Healios K.K. | -3.82 Billion JPY | 108.848% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 128.959% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | 122.708% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | 123.665% |
| StemRIM | -2.02 Billion JPY | 116.729% |
| CellSource Co., Ltd. | 923.14 Million JPY | 63.357% |
| FunPep Company Limited | -933.41 Million JPY | 136.24% |
| Kringle Pharma, Inc. | -854.15 Million JPY | 139.603% |
| Stella Pharma Corporation | -763.74 Million JPY | 144.29% |
| TMS Co., Ltd. | -960.04 Million JPY | 135.235% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | 129.935% |
| Cuorips Inc. | -632.18 Million JPY | 153.508% |
| K Pharma,Inc. | 260.33 Million JPY | -29.937% |
| Takara Bio Inc. | 1.48 Billion JPY | 77.144% |
| ReproCELL Incorporated | -31.41 Million JPY | 1176.766% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | -1182.379% |
| StemCell Institute Inc. | 310.98 Million JPY | -8.774% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | -136.27% |
| CellSeed Inc. | -846.53 Million JPY | 139.959% |